174 related articles for article (PubMed ID: 16208174)
1. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response.
Buscombe JR; Cwikla JB; Caplin ME; Hilson AJ
Nucl Med Commun; 2005 Nov; 26(11):969-76. PubMed ID: 16208174
[TBL] [Abstract][Full Text] [Related]
2. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors.
Buscombe JR; Caplin ME; Hilson AJ
J Nucl Med; 2003 Jan; 44(1):1-6. PubMed ID: 12515868
[TBL] [Abstract][Full Text] [Related]
4. Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy.
Bomanji JB; Wong W; Gaze MN; Cassoni A; Waddington W; Solano J; Ell PJ
Clin Oncol (R Coll Radiol); 2003 Jun; 15(4):193-8. PubMed ID: 12846498
[TBL] [Abstract][Full Text] [Related]
5. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
Castellani MR; Chiti A; Seregni E; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.
Ezziddin S; Sabet A; Logvinski T; Alkawaldeh K; Yong-Hing CJ; Ahmadzadehfar H; Grünwald F; Biersack HJ
J Nucl Med; 2013 Dec; 54(12):2032-8. PubMed ID: 24101685
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders.
Mulholland N; Chakravartty R; Devlin L; Kalogianni E; Corcoran B; Vivian G
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2002-12. PubMed ID: 26142730
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
Kaltsas GA; Mukherjee JJ; Isidori A; Kola B; Plowman PN; Monson JP; Grossman AB; Besser GM
Clin Endocrinol (Oxf); 2002 Aug; 57(2):169-83. PubMed ID: 12153595
[TBL] [Abstract][Full Text] [Related]
9. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans.
Monsieurs M; Brans B; Bacher K; Dierckx R; Thierens H
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1581-7. PubMed ID: 12458391
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of using a standard activity of (131)I-MIBG therapy in patients with disseminated neuroendocrine tumours.
Navalkissoor S; Alhashimi DM; Quigley AM; Caplin ME; Buscombe JR
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):904-12. PubMed ID: 20016892
[TBL] [Abstract][Full Text] [Related]
11. Monitoring the efficacy of iodine-131-MIBG therapy using fluorine-18-FDG-PET.
Menzel C; Graichen S; Berner U; Risse JH; Diehl M; Döbert N; Hamscho N; Grünwald F
Acta Med Austriaca; 2003; 30(2):37-40. PubMed ID: 12752086
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy.
Nguyen C; Faraggi M; Giraudet AL; de Labriolle-Vaylet C; Aparicio T; Rouzet F; Mignon M; Askienazy S; Sobhani I
J Nucl Med; 2004 Oct; 45(10):1660-8. PubMed ID: 15471830
[TBL] [Abstract][Full Text] [Related]
13. Effects of Repeated
Yoshinaga K; Abe T; Okamoto S; Uchiyama Y; Manabe O; Ito YM; Tamura N; Ito N; Yoshioka N; Washino K; Shinohara N; Tamaki N; Shiga T
J Nucl Med; 2021 May; 62(5):685-694. PubMed ID: 33067337
[No Abstract] [Full Text] [Related]
14. Toxicity of high-activity 111In-Octreotide therapy in patients with disseminated neuroendocrine tumours.
Caplin ME; Mielcarek W; Buscombe JR; Jones AL; Croasdale PL; Cooper MS; Burroughs AK; Hilson AW
Nucl Med Commun; 2000 Jan; 21(1):97-102. PubMed ID: 10717909
[TBL] [Abstract][Full Text] [Related]
15. Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of 131I-MIBG.
Ezziddin S; Sabet A; Ko YD; Xun S; Matthies A; Biersack HJ
Radiat Oncol; 2012 Jan; 7():8. PubMed ID: 22277577
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with
Kane A; Thorpe MP; Morse MA; Howard BA; Oldan JD; Zhu J; Wong TZ; Petry NA; Reiman R; Borges-Neto S
J Nucl Med; 2018 Nov; 59(11):1708-1713. PubMed ID: 29777005
[TBL] [Abstract][Full Text] [Related]
17. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.
Loh KC; Fitzgerald PA; Matthay KK; Yeo PP; Price DC
J Endocrinol Invest; 1997 Dec; 20(11):648-58. PubMed ID: 9492103
[TBL] [Abstract][Full Text] [Related]
18. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA
Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341
[TBL] [Abstract][Full Text] [Related]
19. [131I meta-iodobenzylguanidine in combination with hyperbaric oxygen therapy in the treatment of prognostically high-risk forms of neuroblastoma].
Stanková J; Kavan P; Krízová H; Hermanská E; Dosel P; Sázel M
Cas Lek Cesk; 2001 Jan; 140(1):13-7. PubMed ID: 11242978
[TBL] [Abstract][Full Text] [Related]
20. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.
Pasieka JL; McEwan AJ; Rorstad O
Surgery; 2004 Dec; 136(6):1218-26. PubMed ID: 15657579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
